Towards precision medicine in childhood leukemia--insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

Shai Izraeli; Chen Shochat; Noa Tal; Ifat Geron

doi:10.1016/j.canlet.2014.02.009

Towards precision medicine in childhood leukemia--insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia

Cancer Lett. 2014 Sep 28;352(1):15-20. doi: 10.1016/j.canlet.2014.02.009. Epub 2014 Feb 22.

Authors

Shai Izraeli¹, Chen Shochat², Noa Tal³, Ifat Geron⁴

Affiliations

¹ Childhood Leukemia Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. Electronic address: Shai.Izraeli@sheba.health.gov.il.
² Childhood Leukemia Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; Migal Galilee Technology Center, Kiryat Shmona, Israel; Tel Hai College, Upper Galilee 12210, Israel.
³ Childhood Leukemia Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
⁴ Childhood Leukemia Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; Division of Biological Sciences and Department of Medicine Stem Cell Program, University of California San Diego, La Jolla, CA, USA.

PMID: 24569093
DOI: 10.1016/j.canlet.2014.02.009

Abstract

The successful therapy of childhood leukemia has been characterized by careful personalized adaptation of therapy by risk stratification. Yet almost all drugs are relatively non-specific. To achieve greater precision in therapy, druggable targets and specific targeting drugs are necessary. Here we review the recent discoveries of cytokine receptors and their signaling components in high risk leukemias and the potential approaches to target them.

Keywords: Acute lymphoblastic leukemia; CRLF2; Interleukin 7 receptor; Risk stratification.

Publication types

Review

MeSH terms

Genetic Predisposition to Disease
Humans
Precision Medicine / trends*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Receptors, Cytokine / genetics*
Signal Transduction

Substances

Receptors, Cytokine